Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China

OBJECTIVE: This study aimed to estimate the cost–utility of sofosbuvir/velpatasvir (SOF/VEL) compared with other direct-acting antivirals (DAAs) in Chinese patients with hepatitis C virus (HCV). DESIGN: A Markov model was developed to estimate the disease progression of patients with HCV over a life...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Haoya, Zhao, Guoqiang, Sun, Xiaojie, Shi, Lizheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443302/
https://www.ncbi.nlm.nih.gov/pubmed/32819983
http://dx.doi.org/10.1136/bmjopen-2019-035224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443302/
https://www.ncbi.nlm.nih.gov/pubmed/32819983
http://dx.doi.org/10.1136/bmjopen-2019-035224

Ejemplares similares